Taking dalcetrapib after acute coronary syndrome reduces the risk of developing type 2 diabetes

Abstract

Summary with commentary. Citation: Schwartz GG, Leiter LA, Ballantyne CM, et al.

Dalcetrapib reduces the risk of new-onset diabetes in patients with coronary heart disease. Diabetes Care 2020; 43: 1077-1084.

Keywords

• dalcetrapib
• DM2